Press release
Analyzing the Anaplastic Astrocytoma Pipeline and Clinical Trials : 15+ Companies Aiming to Enhance Treatment Space by DelveInsight
Anaplastic Astrocytoma Pipeline
For Anaplastic Astrocytoma Emerging drugs, the Anaplastic Astrocytoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Anaplastic Astrocytoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Anaplastic Astrocytoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Anaplastic Astrocytoma clinical trials studies, Anaplastic Astrocytoma NDA approvals (if any), and product development activities comprising the technology, Anaplastic Astrocytoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Anaplastic Astrocytoma Pipeline Report
• Over 15+ Anaplastic Astrocytoma companies are evaluating 15+ Anaplastic Astrocytoma pipeline therapies in various stages of development, and their anticipated acceptance in the Anaplastic Astrocytoma market would significantly increase market revenue.
• The leading Anaplastic Astrocytoma Companies includes Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Promising Anaplastic Astrocytoma Pipeline Therapies includes Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, and others.
• The Anaplastic Astrocytoma companies and academics that are working to assess challenges and seek opportunities that could influence Anaplastic Astrocytoma R&D. The Anaplastic Astrocytoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
• On Dec 2023, Celgene announced a Phase 1, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics and Central Nervous System (CNS) Penetration of CC-90010 in Preoperative Subjects With Progressive or Recurrent Who Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and Recurrent Glioblastoma Scheduled for Resection.
• On Jan 2022, Orbus Therapeutics announced a Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
To explore more information on the latest breakthroughs in the Me Anaplastic Astrocytoma Pipeline treatment landscape of the report, click here @ Anaplastic Astrocytoma Pipeline Outlook- https://www.delveinsight.com/sample-request/anaplastic-astrocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anaplastic Astrocytoma Overview
Anaplastic Astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. Astrocytes and similar cells form tissue that surrounds and protects other nerve cells found within the brain and spinal cord. Collectively, these cells are known as glial cells and the tissue they form is known as glial tissue. Tumors that arise from glial tissue, including astrocytomas, are collectively referred to as gliomas. The symptoms of Anaplastic Astrocytomas vary depending upon the specific location and size of the tumor. The specific cause of this tumor is unknown.
Recent Developmental Activities in the Anaplastic Astrocytoma Treatment Landscape
• In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).
For further information, refer to the detailed Anaplastic Astrocytoma Unmet Needs, Anaplastic Astrocytoma Market Drivers, and Anaplastic Astrocytoma Market Barriers, click here for Anaplastic Astrocytoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/anaplastic-astrocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anaplastic Astrocytoma Emerging Drugs Profile
• Eflornithine: Orbus Therapeutics
Eflornithine, also known as α-diflurormethylornithine (DFMO), selectively targets and irreversibly inhibits ornithine decarboxylase (ODC), an enzyme essential for polyamine synthesis, and DNA and RNA function. Unlike multi-targeted tyrosine kinase inhibitors on the market or in development, eflornithine targets only one specific enzyme, ODC. In animal studies, eflornithine has been shown to inhibit the growth of malignant tumors, including intra cerebral mid- and high-grade gliomas. Eflornithine administration has also been shown to potentiate the anti-tumor activity of other chemotherapy agents. In single-arm and controlled, randomized clinical trials, eflornithine oral solution increased survival in patients with both newly diagnosed and recurrent anaplastic glioma. The primary and reversible side effects of eflornithine were diarrhea and hearing impairment.
• Zotiraciclib: Cothera Bioscience
Zotiraciclib is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9. In October 2021, Cothera Bioscience Inc. and Adastra Pharmaceuticals Inc., announced a definitive agreement under which Cothera has acquired zotiraciclib (ZTR).
Anaplastic Astrocytoma Pipeline Therapeutics Assessment
There are approx. 15+ key Anaplastic Astrocytoma companies which are developing the therapies for Anaplastic Astrocytoma. The companies which have their Anaplastic Astrocytoma drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics.
Request a sample and discover the recent advances in Anaplastic Astrocytoma Ongoing Clinical Trial Analysis and Medications, click here @ Anaplastic Astrocytoma Treatment Landscape- https://www.delveinsight.com/sample-request/anaplastic-astrocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Anaplastic Astrocytoma Pipeline Report
• Coverage- Global
• Anaplastic Astrocytoma Companies- Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm, Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Anaplastic Astrocytoma Pipeline Therapies- Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, and others.
• Anaplastic Astrocytoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Anaplastic Astrocytoma Market Drivers and Anaplastic Astrocytoma Market Barriers, click here @ Anaplastic Astrocytoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/anaplastic-astrocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Anaplastic astrocytoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anaplastic astrocytoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Eflornithine: Orbus Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GT-10: Geneos Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CLX-ONC-643: Cellix Bio
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Anaplastic astrocytoma Key Companies
21. Anaplastic astrocytoma Key Products
22. Anaplastic astrocytoma- Unmet Needs
23. Anaplastic astrocytoma- Market Drivers and Barriers
24. Anaplastic astrocytoma- Future Perspectives and Conclusion
25. Anaplastic astrocytoma Analyst Views
26. Anaplastic astrocytoma Key Companies
27. Appendix
Got Queries? Find out the related information on Anaplastic Astrocytoma Mergers and acquisitions, Anaplastic Astrocytoma Licensing Activities @ Anaplastic Astrocytoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/anaplastic-astrocytoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Related Reports:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Analyzing the Anaplastic Astrocytoma Pipeline and Clinical Trials : 15+ Companies Aiming to Enhance Treatment Space by DelveInsight here
News-ID: 3348722 • Views: …
More Releases from DelveInsight Business Research
Friedreich Ataxia Market Trends Point to Steady Growth Ahead by 2034, DelveInsig …
The Friedreich's Ataxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Friedreich's Ataxia pipeline products will significantly revolutionize Friedreich's Ataxia market dynamics.
DelveInsight's "Friedreich's Ataxia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as the Friedreich's Ataxia market trends in the United States,…
Cell and Gene Therapies in Rare Disorders Market Dynamics Indicate Upward Trajec …
DelveInsight's "Cell and Gene Therapies in Rare Disorders Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cell and Gene Therapies in Rare Disorders, historical and forecasted epidemiology as well as the Cell and Gene Therapies in Rare Disorders market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Cell and Gene Therapies in…
AL Amyloidosis Market to Witness Promising Upswing by 2034, DelveInsight Forecas …
DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology as well as the AL Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the AL Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; AL Amyloidosis Market Forecast
https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Mucopolysaccharidosis Market Growth to Surge During Forecast Period (2024-2034), …
DelveInsight's "Mucopolysaccharidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Mucopolysaccharidosis, historical and forecasted epidemiology as well as the Mucopolysaccharidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Mucopolysaccharidosis, offering comprehensive insights into the Mucopolysaccharidosis revenue trends, prevalence, and treatment landscape. The report delves into key Mucopolysaccharidosis…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
